No, we're not.
When we needed extra time to be able to do a study, we very openly talked about it. We've also agreed in that committee that we'll extend the women's health study. One of our colleagues who was here from that committee, Madam Goodridge, suggested an excellent two-day study, a two-session study, on women's breast cancer, and then we are going to the research. I don't think there would be any issues, once this motion has been referred to the HESA committee, in extending the existing committee work on opioids by a few sessions to be able to go through the contracts and have that deep dive that we need to do.
Also, there is precedence in that committee for us to look at contracts. We looked at Medicago and we looked at other contracts related to COVID. Just the fact that it's related to contracts doesn't mean that it has to come to OGGO only; it can go to HESA.
I'll be brief, rather than repeat myself. There is an ongoing study, as my colleague said. We've never had an issue when a worthy study and a worthy motion has come to HESA to be looked at. I'll be supporting this motion when it goes to HESA to be looked at. Just because it has to do with a contract.... HESA's never had an issue with looking at that aspect of a study, so I strongly suggest that we forward this motion to HESA. I'm sure that with Dr. Ellis's support and Madam Goodridge's support, we will be in a position to be able to extend the study and do a deep dive on this.
Thank you, Mr. Chair.